A Donor Heart Cell Therapy Slowed Arm Function Loss in Advanced Duchenne, but FDA Advisers Voted Against It

The HOPE-3 trial met its primary endpoint in advanced Duchenne, yet an FDA advisory committee voted nine to three against the therapy.

Have A Referral?